Find Funding Opportunities
COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.
Learn more about award types and program directors and managers.
NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!
For more focused results add quotes to indicate parameters. Example format: "search term".
Request Information RFI): NIH Countermeasures Against Chemical Threats CounterACT) Investigator-Industry Partnerships Notice Number: NOT-NS-16-005 Key Dates Release Date: February 3, 2016 Response Date: February 29, 2016 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose is time sensitive Request Information RFI) solicit feedback pharmaceutical biotechnology companies regarding potential convening a meeting facilitate partnerships between active NIH CounterACT investigators entities the commercial industrial sectors. Background mission the NIH Countermeasures Against Chemical Threats CounterACT) program to develop new improved therapeutics treat and/or prevent injuries resulting exposure chemical threats. Chemical threats toxic chemicals could used a terrorist attack accidentally released industrial production, storage shipping. include traditional chemical warfare agents toxic industrial chemicals materials. chemical threats a variety effects. Classes chemicals encompass cholinesterase GABA-inhibitors can induce prolonged uncontrolled excitation the nervous system, metabolic/cellular poisons prevent cellular respiration, vesicating agents cause moderate debilitating ocular, dermal, mucosal injuries, pulmonary compounds corrosively injure, irritate, react the lining the respiratory tract. NIH CounterACT projects developing candidate therapeutics are poised more advanced development activities, including pre-Investigational New Drug pre-IND)-enabling clinical studies could supported other federal agencies fund advanced development, FDA approval licensure, well procurement activities under Project BioShield medical countermeasures.gov). majority projects supported NIH in academic labs often not possess resources expertise these types advanced studies. address need, is critical the NIH facilitate partnerships between academic laboratories pharmaceutical biotechnology companies typically more experience drug development regulatory approval. Please CounterACT Projects a list active projects. Note not of projects mature enough engaging industry. there general interest an Investigator-Industry Partnership meeting, information specific projects are ready engagement industry be provided a method be determined. Information Requested NIH especially interested identifying facilitating establishment partnerships between funded researchers industrial entities. partnerships aid the successful development approved medical countermeasure products the sustainability the overall research enterprise. NIH seeks input specifically industry stakeholders potential interest attending meeting specific NIH CounterACT investigators ready partnerships. achieve goal this time-sensitive RFI, invite comments any all the following areas: 1. Interest attending presentations NIH CounterACT investigators regarding lead candidate therapeutics 2. The most important characteristics a project would influence interest a product under development. example, is type product, market beyond biodefense, available non-dilutive funding including federal, etc.? 3. Please provide any comments specific features the meeting would most useful. 4. Please provide any comments this proposed initiative respondents feel relevant. meeting also include presentations federal government officials the various funding programs available support advanced development medical products within mission. to Submit Response Responses this RFI must submitted electronically Dr. Shardell Spriggs shardell.spriggs@nih.gov later February 29, 2016. Reference Notice number NOT-NS-16-005) the subject line the email. Responses this RFI voluntary. RFI for planning purposes only should be construed a solicitation as obligation the part the Federal Government, National Institutes Health, individual NIH institutes Centers. NIH does intend make any type award based responses this RFI to pay either preparation information submitted the Government’s of such information. NIH use information submitted response the RFI its discretion. Respondents advised the Government under obligation acknowledge receipt the information provided will provide feedback respondents. information submitted be analyzed may shared internally used NIH CounterACT staff planning future Investigator-Industry Partnership meetings, appropriate at Government’s discretion. Proprietary, classified, confidential, sensitive information should be included your response. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035 Email: david.jett@nih.gov